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1. Introduction 
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is the most common 
form of motor neuron disease. It is a debilitating, late onset neurodegenerative disorder that is 
characterized by the progressive death of upper and ǂ-motor neurons within the central 
nervous system (CNS) (Bruijn and Cleveland, 1996). This results in symptoms of muscle 
weakness and atrophy of skeletal muscles, leading to paralysis and eventual death due to 
failure of respiratory muscles (Cozzolino et al., 2008). ALS has a prevalence of approximately 
1~2 per 100,000 worldwide with males being more susceptible than females (1.3 ~ 1.6: 1) 
(Strong, 2003, Woodruff et al., 2008b, Worms, 2001). The majority of ALS cases (~90%) are 
thought to be sporadic with unknown aetiology and no robust environmental risk factors, 
with the remaining 10% being familial ALS. Of this 10%, approximately 20% have been linked 
to dominant mis-sense point mutations in the Copper/Zinc superoxide dismutase 1 (SOD1) 
gene which results in a gain of unidentified deleterious properties (Rosen et al., 1993). The two 
aetiologies of ALS (i.e. sporadic and familial) are indistinguishable on the basis of their clinical 
and pathological features, including progressive muscle weakness, atrophy and spasticity, 
each of which reflects the degeneration and death of upper and ǂ-motor neurons (Boillee et al., 
2006). The mechanisms leading to ALS are still unclear but theories have suggested that 
glutamate excitoxicity, oxidative stress, protein aggregation, mitochondrial dysfunction, 
cytoskeletal abnormalities and neuro-inflammation may all play a role (Bruijn et al., 2004). The 
present chapter will review the role of innate immune system, in particular the complement 
system, during the disease progression of ALS. It will review evidence for an involvement of 
the innate immune Toll-like receptor (TLR) system and receptor for advanced glycosylation 
end products (RAGE) in ALS patients and animal models of ALS. It will also comprehensively 
evaluate the role of the innate immune complement cascade in this disease. Finally, the future 
therapeutic possibilities for ALS, aimed at targeting components of the innate immune system 
will be discussed. We provide compelling evidence for specific inhibitors of complement C5a 
receptors as novel treatment strategies for ALS. 
2. Innate immunity in neurodegenerative disease 
Innate immunity is an evolutionary ancient system that provides the host with immediately 
available defence mechanisms. It is a rapid and coordinated cascade of reactions by host 
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cells to protect them against foreign pathogens and insults (Akira et al., 2001, Nguyen et al., 
2004). Until recently, the CNS was considered to be immunologically privileged because of 
its inability to mount an immune response and process antigens. Recent studies have 
revealed that immune surveillance and differentiation between self and non-self does take 
place in the CNS, where glial cells, including microglia, astrocytes and oligodendrocytes, act 
as CNS immune effector cells (Hanisch et al., 2008, Lehnardt, 2010, Ricklin et al., 2010).  
The role of innate immune system in the CNS is mainly to provide protection to the neurons 
from foreign pathogens and injurious stimuli, and to maintain CNS homeostasis. It is also 
required for tissue modelling during development and following injury (Benard et al., 2008, 
Mastellos et al., 2005, Rahpeymai et al., 2006, Stevens et al., 2007). However sustained 
chronic inflammation might be harmful for neuronal integrity and may result in cellular 
dysfunction which triggers neurodegeneration. There is increasing evidence that suggests 
an involvement of the innate immune system in the development of neuro-inflammation 
which may drive the progression of many neurodegenerative diseases including ALS. Two 
major constituents of innate immune system are the TLRs and the complement cascade, each 
of which are described below. 
3. Toll-like receptors (TLRs) and receptor for advanced glycosylation end 
products (RAGE) in ALS 
TLRs are a large family of evolutionarily conserved transmembrane glycoproteins that 
initiate immune responses for host defence upon activation. These receptors are pattern 
recognition receptors that recognise pathogen-associated molecular patterns (PAMPs) from 
diverse organisms including bacteria, viruses, fungi and parasites (Liew et al., 2005). TLRs 
are expressed in various cell types in the CNS including microglia, astrocytes, 
oligodendrocytes and neurons (Aravalli et al., 2007, Bowman et al., 2003, Olson and Miller, 
2004, Tang et al., 2007). This pathway has recently been implicated in the pathogenesis of 
ALS. Increased levels of TLRs (TLR1, TLR2, TLR5, TLR7 and TLR9) have been observed in 
mutant SOD1 mice as compared to controls (Letiembre et al., 2009) and mutant SOD1 
expression in ALS has been suggested to facilitate microglial neurotoxic inflammatory 
responses via TLR2 (Liu et al., 2009). In addition, it has recently been shown that mutant 
SOD1 binds to CD14, which is a co-receptor of TLR2 and TLR4, and that microglial 
activation mediated by mutant SOD1 (G93A) can be attenuated using TLR2, TLR4 and CD14 
blocking antibodies (Zhao et al., 2010). The involvement of TLR signalling in the 
pathogenesis of ALS is also supported by up-regulation of TLR2 and TLR4 mRNA and 
protein in the ALS patients, compared to control spinal cords. The increased expression 
level of TLR2 and TLR4 was shown on microglia and reactive astrocytes respectively 
(Casula et al., 2011). This suggests that TLRs could play a role in the progressive 
degeneration of motor neurons in ALS and indicates that the innate immune system is 
important in sensing neuronal injury and driving the progression of this disease. 
In absence of pathogens, TLR signalling can also be activated via molecules called damage 
associated molecular patterns (DAMPs) including the high mobility group box 1 (HMGB1) 
protein released by injured tissues (Bianchi and Manfredi, 2009). HMGB1 is a nearly ubiquitous 
chromatin component that can regulate transcription of different sets of genes, including pro-
inflammatory genes (Bianchi and Manfredi, 2009, Mouri et al., 2008). It can also be released 
passively by necrotic cells and actively secreted by stimulated monocytes/macrophages and 
astrocytes, which then bind to RAGE, TLR2 and TLR4. (Andersson et al., 2008, Hreggvidsdottir 
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et al., 2009, Parker et al., 2004, Scaffidi et al., 2002). Therefore, HMGB1 can act as a potent pro-
inflammatory cytokine-like mediator, thus contributing to amplification of the inflammatory 
response (Bianchi and Manfredi, 2007, Hreggvidsdottir et al., 2009). HMGB1-RAGE signalling 
has also been implicated in the progression of ALS where there was a significant increase in 
HMGB1 mRNA expression in ALS patient spinal cords when compared to normal individuals 
(Casula et al., 2011). The increased expression of HMGB1 was expressed by activated microglia 
and astrocytes in the spinal cord (Casula et al., 2011). Interestingly, there were no significant 
changes in RAGE mRNA expression in 12 ALS patients when compared to 6 controls. This 
observation could be due to the loss of motor neurons expressing RAGE in ALS patients, thus 
reducing the endogenous pool of RAGE mRNA. This same study also demonstrated that there 
is an increased expression of RAGE on astrocytes and microglia when compared to controls 
(Casula et al., 2011). Furthermore, serum soluble RAGE (sRAGE) levels were decreased in the 
serum of ALS patients when compared to normal individuals, where sRAGE is known to be a 
possible modulator of inflammation in several diseases (Ilzecka, 2009). Hence it is possible that 
low sRAGE levels may accelerate the neurodegeneration and could be a risk factor in ALS. This 
suggests that TLR/RAGE signalling may play a role in the disease progression of ALS, by 
activating microglia and astrocytes in the vicinity of motor neuron death. Targeting TLRs and 
RAGE may therefore be a novel therapeutic strategy to treat degenerative neuronal loss 
occurring in ALS. 
4. The complement system in the CNS 
The complement system is a key component of the innate immune system, which 
participates in the recognition, trafficking and elimination of pathogens and unwanted host 
materials. The complement system is an enzymatic cascade consisting of more than 30 
plasma proteins and glycoproteins, and either soluble or membrane-bound receptors (Guo 
and Ward, 2005). Complement activation participates in host defence against pathogens 
primarily by cytotoxic and cytolytic activity through triggering formation of the membrane 
attack complex (MAC or C5b-9) on the target cell membrane (van Beek et al., 2003). It is 
activated via three major pathways: the classical, alternative, and lectin pathways; it is also 
activated by a recently identified fourth, extrinsic protease pathway (Huber-Lang et al., 
2006, Thoman et al., 1984) (Figure 1).   
The classical pathway is primarily activated in response to the recognition molecule C1q 
binding to antigen-antibody complexes such as immunoglobins (IgG and IgM) and 
pentraxins (such as C-reactive protein) bound to their targets (Ricklin et al., 2010, Woodruff 
et al., 2010). C1q may also bind directly to pathogen surfaces and to non-pathogen surfaces 
such as beta-amyloid and liposomes (Jiang et al., 1994, Marjan et al., 1994). The alternative 
pathway is activated by foreign surfaces which amplifies the slow spontaneous hydrolysis 
of C3 which leads to the formation of C3 convertases (Pangburn et al., 1981, Ricklin et al., 
2010), whereas lectin pathway is initiated following the binding of mannose-binding lectin 
to carbohydrate groups on the surfaces of some pathogens (Woodruff et al., 2010). The 
activation of each of these pathways results in assembly of C3 and C5 convertase enzymes 
which cleave their respective inactive complement factors C3 and C5 into their active 
fragments C3a, C3b, C5a and C5b. This leads to the formation of MAC through the non-
enzymatic assembly of C5b with complement factors C6-C9, forming C5b-9 on the cell 
membrane, which creates a transmembrane pore, ultimately leading to cell lysis (Podack et 
al., 1982). A recently identified fourth extrinsic pathway involves direct cleavage of 
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complement 3 (C3) and complement 5 (C5) into C3a/C3b and C5a/C5b by proteolytic 
enzymes (serine proteases) such as kallikrein, thrombin and cell-derived proteases (Huber-
Lang et al., 2002, Huber-Lang et al., 2006). As a result, synthesis of C5 by local inflammatory 
cells can produce C5a via cleavage of C5 with cell derived proteases, even when devoid of 
the complement cascade precursor, C3 (Huber-Lang et al., 2006). This pathway may provide 
a source of complement activation factors in the absence of upstream complement 
activation, and in a local tissue environment such as the CNS (Woodruff et al., 2010). 
 
 
Fig. 1. Complement Cascade: Complement is part of the innate immune system and can be 
activated via four different pathways: the classical pathway, an antigen-antibody complex; 
the alternative pathway, activated by bacteria and foreign surfaces; the lectin pathway 
activated by mannose binding lectin; and recently discovered extrinsic protease pathway 
involving direct cleavage of C3 and C5. Each pathway converges at C3 and leads to a 
common terminal point which involves the formation of the cytolytic membrane attack 
complex (MAC) leading to cell lysis. Formation of pro-inflammatory anaphylatoxins C3a 
and C5a induces glial chemotaxis, generation of superoxide radicals and release of 
inflammatory mediators. C3b and iC3b facilitates phagocytosis by opsonising foreign 
pathogens. 
The primary function of complement activation is to provide a rapid response to infection 
and injury by initiating the production of opsonins C1q and C3b to opsonise pathogens, the 
production of the pro-inflammatory anaphylatoxins C3a and C5a to recruit immune and 
inflammatory cells through ligand-receptor interactions with their corresponding receptors, 
C3aR and CD88, and the formation of cytolytic MAC, which ultimately leads to the 
destruction of invading organisms by cell apoptosis/necrosis (Liszewski et al., 1996). 
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C5a is considered to be the most potent inflammatory molecule generated upon 
complement activation and exhibits a broad range of functions. C5a exerts its effect through 
two high affinity receptors, the classical C5aR (CD88), and the C5a-like receptor 2 
(C5L2/GPR77). The main C5a receptor, CD88 is a member of the rhodopsin family of seven 
transmembrane domain receptors coupled to the hetero-metric G proteins of the Gi subtype: 
pertussis toxin-sensitive Gǂi2, Gǂi3 or pertussis toxin-insensitive Gǂ16 (Amatruda et al., 1993, 
Johswich and Klos, 2007, Rollins et al., 1991). Cellular activation of CD88 involves 
intracellular calcium mobilization and activation of different signaling pathways including 
phosphatidylinositol-3-kinase/Akt (PI3KǄ; Perianayagam et al., 2002), Ras/B-Raf/mitogen-
activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) (Buhl et al., 
1994), phospholipase A2, phospholipase D (Cockcroft, 1992, Mullmann et al., 1990), protein 
kinase C (PKC; Buhl et al., 1994), p21-activated kinases, Rac GTPases (Huang et al., 1998), 
signal transducers and activators of transcription, sphingosine kinase (Melendez and 
Ibrahim, 2004) and NF-κB (Kastl et al., 2006). It is widely expressed on variety of cells and 
tissues, and its activation is known to have pro-inflammatory functions such as chemotaxis, 
degranulation, superoxide production, and release of proteases, eicosanoids, cytokines and 
chemokines from inflammatory cells (Gomez-Cambronero et al., 2007, Melendez and 
Ibrahim, 2004, Torres and Forman, 1999, Tsai et al., 2004). 
The recently discovered C5a receptor, C5L2 has the conventional G-protein coupled receptor 
structure but it is not coupled to intracellular G-protein activated signaling pathways 
(Bamberg et al., 2010, Okinaga et al., 2003). Binding of C5a to C5L2 failed to induce 
intracellular calcium mobilization, extracellular signal-related kinase phosphorylation or 
receptor internalization, by contrast to CD88 (Cain and Monk, 2002, Okinaga et al., 2003). 
This has led to the proposal that C5L2 may act as a decoy anaphylatoxin receptor by 
regulating the availability of C5a to CD88, or by forming oligomers with CD88 to interrupt 
C5a-CD88 signaling (Rabiet et al., 2007). Although the mechanisms underlying C5L2 
activation are still unknown, several recent studies in C5L2 knockout mice have showed 
greater response to C5a, a greater influx of inflammatory cells and a greater release of IL-6 
and TNF-ǂ compared to the wild-type mice (Rabiet et al., 2007). This suggests that C5a 
signaling via C5L2 may exert anti- inflammatory functions which buffer the effects of the 
inflammatory C5a-CD88 signaling pathway (Rabiet et al., 2007). Furthermore, studies have 
shown that C5L2 may function as an intracellular receptor, which becomes activated only 
after ligand binds to CD88. It was suggested that C5L2 negatively modulates C5a-CD88 
signaling and limits the signaling capacity of C5a via its interaction with CD88 and ǃ-
arrestins (Bamberg et al., 2010, Van Lith et al., 2009). Any role for C5L2 in 
neurodegenerative diseases has yet to be properly elucidated. 
Although the CNS does not receive the same composition of circulating complement factors 
synthesised in the liver by hepatocytes, due to the blood brain barrier (BBB), many studies 
have revealed that the CNS contains components of complement cascade, where they are 
expressed by astrocytes, microglia, oligodendrocytes and neurons (Barnum, 1995, Gasque et 
al., 1997, Nataf et al., 2001, O'Barr et al., 2001). Similar to the peripheral system, the role of 
complement activation within the CNS is thought to primarily protect the neurons from 
foreign pathogens through activation of inflammatory and immune cascades by 
surrounding glial cells. In addition to their immune surveillance functions, recent studies 
have shown that complement molecules also have a role in adaptive immune response, 
nervous system development, regeneration and regulating CNS homeostasis by clearing 
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cellular debris and also eliminating excess synapses (i.e. synaptic pruning) (Stevens et al., 
2007). Intriguingly, synaptic loss is not only a feature of neural development but is also a 
key pathological feature of neurodegenerative diseases (Schafer and Stevens, 2010, 
Woodruff et al., 2010). Hence it has been proposed that complement has multiple central 
roles in the CNS other than its canonical functions associated with host defence (Benard et 
al., 2008, Rahpeymai et al., 2006, Stevens et al., 2007). Therefore dysregulation or imbalance 
of the complement system in the CNS can be harmful to the neurons and may lead to, or 
contribute to, neurodegenerative diseases including ALS. 
5. Clinical evidence of complement involvement in ALS 
Several studies have been conducted on ALS patients in an attempt to identify whether 
complement components are up-regulated in disease progression (Table 1). It has been 
proposed that the classical complement system is involved in the pathophysiology of ALS, 
as studies have shown that activation fragments of complement components C3 and C4 are 
increased in the serum, cerebrospinal fluid (CSF), and neurological tissue (including spinal 
cord and motor cortex) of ALS patients (Annunziata and Volpi, 1985, Apostolski et al., 1991, 
Goldknopf et al., 2006, Kawamata et al., 1992, Trbojevic-Cepe et al., 1998). The first of these 
studies examined C3 immunofluorescence in spinal cord and motor cortex of 16 ALS 
patients and demonstrated significant C3 deposition, which appeared to be on astrocyte-like 
cells with no apparent neuronal staining (Donnenfeld et al., 1984). Subsequent studies 
measured C3c, C4, C1 inactivator and C3 activator fractions in the serum and CSF of 13 ALS 
patients but only detected increased levels of C3c in the CSF of ALS patients compared to 
normal individuals (Annunziata and Volpi, 1985). Furthermore Apopstolski and colleagues 
(1991) measured serum C4, C3 and Factor B levels in 33 ALS patients and found an increase 
in C4 levels when compared to normal individuals. Increased clusters of C3d and C4d 
coated fibers on oligodendroglia and degenerating neurites in spinal cord and motor cortex 
was also found in 8 ALS patients compared to 5 normal individuals (Kawamata et al., 1992). 
Two separate studies also investigated C1q, C4d and C4 levels in the serum and CSF of ALS 
patients and found C4d levels significantly increased in 15 ALS patients which also 
correlated with disease severity (Tsuboi and Yamada, 1994); another study also detected 
upregulation of C4 in ALS patients (Trbojevic-Cepe et al., 1998). Studies by Grewal and 
colleagues (Grewal et al., 1999) and Jiang and colleagues (Jiang et al., 2005) have identified 
increased mRNA of upstream complement components (C1q and C2) in the spinal cord of 
ALS patients. Recently, Sta and colleagues have found increased levels of C1q, C3c, C3d and 
C5b-9 in the spinal cord and motor cortex of ALS patients compared to normal individuals 
(Sta et al., 2011). The expression of these complement components was observed in glial cells 
rather than neurons (Sta et al., 2011). Lastly, complement component C3 was also found to 
be upregulated in the CSF of 71 ALS patients when compared to 40 normal individuals 
(Ganesalingam et al., 2011).  
These findings of upregulated complement components and activation fragments, 
predominantly composing the classical pathway, in the serum, CSF, and neurological tissue 
in ALS patients strongly suggest that the classical complement pathway is involved in the 
progression of disease in ALS. However it is currently unknown where these complement 
factors originate, and what initiates their activation. Complement factors can be produced 
by various cells of the CNS and thus these complement factors could be produced locally in 
response to disturbance in CNS homeostasis due to immunoglobulin deposits and auto-
www.intechopen.com
 Innate Immunity in ALS 
 
399 
antibodies in the CNS of ALS patients (Donnenfeld et al., 1984, Niebroj-Dobosz et al., 2006). 
Also the circulation could be a source of these complement factors as there is BBB 
breakdown in the end stages of ALS (Apostolski et al., 1991). Overall, evidence from these 
clinical studies helps us to propose that complement system activation occurs in ALS 
patients, and may play a role in the disease pathology. This is also supported by evidence of 
studies showing involvement of complement factors in animal models of ALS. 
 
Complement 
factors 
mRNA/Protein Sample Methods 
C3 Protein 
Spinal Cord, 
Motor cortex 
Immunofluorescence 
C3c Protein Serum, CSF 
Single radial immuno-
diffusion 
C4 Protein Serum 
Single radial immuno-
diffusion 
C3d, C4d Protein 
Spinal Cord, 
Motor cortex 
Immunohistochemistry 
C4d Protein CSF Sandwich ELISA 
C4 Protein CSF Laser nephelometry 
C1q mRNA 
Spinal Cord, 
Motor cortex 
Northern blot, In situ 
hybridization 
C2 mRNA Spinal Cord Microarray 
C3c, C3dg, 
Factor H 
Protein Serum 2D gel electrophoresis 
C1q, C3c, C3d, 
C5b-9 
mRNA/Protein 
Spinal Cord, 
Motor cortex 
qPCR, immunohistochemistry 
C3 Protein CSF Sandwich ELISA 
Table 1. Clinical evidence of complement activation in ALS patients 
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6. Experimental evidence of complement involvement in ALS 
Many studies in animal models of ALS have shown the involvement of the complement 
system during disease progression, supporting findings in ALS patients (Table 2). Although 
the SOD1 gene mutation only accounts for 2% of total ALS cases, mouse models carrying 
over-expression of mutant SOD1 enzyme are widely used, as it leads to progressive 
symptoms which are very similar to the human condition.  
 
Complement 
factors 
mRNA/Protein Transgenic model Reference 
C1q mRNA Mouse SOD1 G93A (Perrin et al., 2005) 
C1q, DAF mRNA 
Mouse SOD1 G37R and 
SOD1 G85R 
(Lobsiger et al., 2007) 
C1q, C4 mRNA/Protein Mouse SOD1 G93A (Ferraiuolo et al., 2007) 
C1q mRNA Mouse SOD1 L126delTT (Fukada et al., 2007) 
CD88 mRNA/Protein Rat SOD1 G93A (Woodruff et al., 2008a) 
CD88 mRNA/Protein Mouse NFL -/- (Humayun et al., 2009) 
C1q, C3 mRNA/Protein Mouse SOD1 G93A (Heurich et al., 2011) 
Table 2. Experimental evidence of complement activation in animal models of ALS 
The first study to demonstrate experimentally the involvement of complement factors in a 
SOD1 transgenic mouse model was performed by Perrin and colleagues in 2005. They 
isolated the ventral motor neurons from the lumbar spinal cord of SOD1G93A transgenic 
mouse using laser-capture micro-dissection and then using microarray analysis they 
detected increased levels of all subcomponents of C1q in these mice at early symptomatic 
and end stage when compared to motor neurons from wild-type mice (~5 and ~8 fold 
respectively) (Perrin et al., 2005).  
Subsequent studies in two distinct SOD1 transgenic mouse models also used laser-capture 
micro-dissection to isolate lumbar motor neurons from SOD1G37R and SOD1G85R transgenic 
mice which showed upregulation of genes for all three C1q subcomponents when compared 
to SOD1WT mice 2 months prior to clinical onset (P105) (Lobsiger et al., 2007). In addition, 
this group demonstrated that the complement regulatory molecule, decay accelerating 
factor (DAF) also decreased at this time point (Lobsiger et al., 2007). Furthermore they 
showed that C1q protein was expressed by motor neurons using immunohistochemistry on 
spinal cord sections of both SOD1G37R and SOD1G85R transgenic mice but absent in the age-
matched control mice (Lobsiger et al., 2007). 
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A separate group also used laser-capture microdissection to isolate the lumbar motor 
neurons from SOD1G93A transgenic mice. Using microarray analysis and real time 
quantitative PCR, they showed there were increased levels of C1q (subcomponent B) and C4 
mRNA at disease onset (P90) and late-stage disease (P120) (~7 and ~8 fold respectively) 
(Ferraiuolo et al., 2007). A similar study also used microarray analysis in a separate SOD1 
transgenic mouse model using whole lumbar spinal cord homogenate (Fukada et al., 2007). 
This study used SOD1L126delTT transgenic mice and showed elevated levels of C1q 
(subcomponent B) mRNA in post-symptomatic (P154) mice compared to wild-type mice. A 
very recent study has shown increased levels of C1q in the neuromuscular junction of 
SOD1G93A transgenic mice compared to wild-type mice (Heurich et al., 2011). 
By contrast to the above studies, which indicates a role for the classical complement 
pathway in the progression of pathology of the SOD1 transgenic mouse, a recent study has 
demonstrated that when SOD1G93A transgenic mice were bred onto a background deficient 
in complement C4 (a necessary component of the classical complement pathway, 
downstream of C1q), there was a difference in the macrophage levels and activation in the 
peripheral nervous system but no difference in the onset of motor symptoms and survival 
when compared to wild-type mice (Chiu et al., 2009). This study indicates that other 
molecular pathways such as the alternative or extrinsic pathway may play compensatory 
roles in immune activation and macrophage recruitment in the absence of the classical 
pathway in these mice. To support this, recent studies in SOD1G93A transgenic mouse 
showed increases in the C3 mRNA and protein levels in the spinal cord when compared to 
wild-type animals at symptomatic stage (P126) (Heurich et al., 2011). They also observed 
upregulation of C3 at the motor end plate and nerve terminals in the SOD1G93A transgenic 
mice at pre-symptomatic stage (P47) when compared to wild-type animal (Heurich et al., 
2011). 
To further validate the involvement of downstream components of the complement cascade 
in the disease progression of ALS, upregulation of C5a receptor CD88 mRNA and protein 
was observed in mice deficient in the low molecular weight neurofilament (NFL) subunit 
protein, a mouse model of motor neuron degeneration in which neurofilament aggregates in 
a similar fashion to that in ALS patients (Humayun et al., 2009). This study showed there 
was a 4 and 3 fold increase in CD88 mRNA expression level at 2 and 3 months respectively, 
a time which is early in the disease process (Humayun et al., 2009). There was also an 
increased immunoreactivity of CD88 in motor neurons of NFL deficient mice when 
compared to wild-type mice at 3, 4 and 5 months. Our own findings also support a 
pathogenic role for C5a in ALS (Woodruff et al., 2008a). Chronic administration of a specific 
C5a receptor antagonist, developed in our laboratories (Wong et al., 1998) in SOD1G93A 
transgenic rats, markedly delayed the onset of motor symptoms and increased survival, 
compared to untreated animals (Woodruff et al., 2008a). We also showed upregulation of 
CD88 in the lumbar spinal cord of SOD1G93A transgenic rats, which increased as disease 
progressed (Woodruff et al., 2008a). 
These findings of upregulated complement components in different animal models of ALS 
suggest that the activation of complement system is critically linked with disease 
progression in ALS. Whilst inhibition of one component of the classical and lectin 
complement pathway, C4, failed to ameliorate disease in SOD1G93A transgenic mice, 
inhibition of the classical receptor for C5a, CD88, reduced disease pathology in SOD1G93A 
transgenic rats. It should be noted that C5a is expressed following activation of all 
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complement pathways (Figure 1). Hence inhibiting central components of the complement 
system, at the C3 and C5 level, may have benefits in slowing disease progression in ALS, as 
opposed to inhibiting an individual activation pathway. Specifically, our studies suggest 
that inhibiting the pro-inflammatory C5 activation fragment, C5a, which is central to, and 
generated by, all complement pathways, may be a novel therapeutic strategy to treat ALS. 
7. Future directions: Therapeutic applications 
To date, riluzole (Rilutek, Aventis Pharmaceuticals Inc) is the only approved therapeutic to 
treat ALS; it is known to prevent the pre-synaptic release of glutamine (Bellingham, 2011, 
Miller et al., 2007). In clinical trials, it has been shown to extend survival by around 2 ~ 3 
months and delay the onset of ventilator dependence or tracheostomy (Bellingham, 2011, 
Miller et al., 2007). It is not clear that the drug improves the quality of life, however. Given 
this modest extension of ~2-3 months in survival there is an urgent need to develop new 
therapeutics which will significantly extend survival and also decrease morbidity in ALS.  
Recent studies have suggested that the innate immune system is important in sensing ALS 
progression and its subsequent upregulation may drive the progression of this disease 
(Woodruff et al., 2008b). The complement system would be a logical and viable pathway to 
target, given the steadily accumulating clinical evidence of complement involvement in this 
disease.  This is also supported by our findings where using specific C5a receptor antagonist 
improved motor symptoms and extended survival in the SOD1G93A transgenic rat (Woodruff 
et al., 2008a). 
Our laboratories have developed a series of cyclic peptide C5a receptor antagonists which 
are potent inhibitors of C5a receptors on human inflammatory cells (Woodruff et al., 2011). 
PMX53 (AcF-[OPdChaWR] and PMX205 (hydrocinnamate-[OPdChaWR]) are orally active 
cyclic hexapeptides, which were derived from the linear CD88 antagonist, Me-FKPdChaWR 
(Konteatis et al., 1994) that were cyclised to induce structural and metabolic stability(Finch 
et al., 1999, March et al., 2004). These drugs have been shown to display therapeutic efficacy 
in numerous rodent models of inflammatory disease including rheumatoid arthritis 
(Woodruff et al., 2002), ischemic reperfusion injuries (Arumugam et al., 2004) and 
inflammatory bowel disease (Woodruff et al., 2003), as well as acute neurodegeneration 
(Woodruff et al., 2006). PMX205 is more lipophilic than the original CD88 antagonist 
PMX53, which results in increased potency in certain inflammatory models (Woodruff et al., 
2005) and increased CNS penetrance (Woodruff et al., 2006). Hence, it has been used to 
reduce disease severity and prolong survival in animal models of neural degeneration 
including Huntington’s disease, Alzheimer’s disease and ALS (Ager et al., 2010, Fonseca et 
al., 2009, Woodruff et al., 2006, Woodruff et al., 2008a). As a result of this work, PMX205 
would be the particular PMX series compound we would promote for any future clinical 
trialling in ALS. 
In addition to inhibiting C5a receptors, targeting other factors of the complement system 
may provide viable therapeutic options to treat ALS.  Several complement inhibitors have 
been developed over the years and compounds such as sCR1, C5 antibodies, compstatin or 
others could be used as potential therapies for ALS. However, due to the need to chronically 
administer a drug in ALS, a small, orally active and BBB permeable complement inhibitor, 
such as PMX205, would be required. The selectivity of PMX205 towards the classical C5a 
receptor leaves other components of the complement system intact, allowing for the 
production of complement factors including the MAC, thus reducing immune suppression - 
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a likely side effect of other inhibitors of complement which act more upstream in the system, 
were they are to be used chronically. Finally, PMX53, an analogue to PMX205 has already 
been shown to be safe when administered to humans, successfully completing three Phase 
I/IIa clinical trials, thus promoting the safety of these classes of drugs in humans (Woodruff 
et al., 2011). 
In addition to anti-complement agents, combined therapies targeting multiple and disparate 
pathways will most likely be needed to effectively treat ALS. Extensive controlled clinical 
trials will need to be conducted in order to ascertain any potential therapeutic benefit of a 
complement inhibitor to treat the devastating and intractable nature of ALS. 
8. Conclusion 
There is increasing evidence that implicates the involvement of the innate immune system in 
the progression of ALS. In particular, the inappropriate activation or dysregulation of the 
complement system may play a role in ALS pathology. Evidence for this includes elevated 
levels of complement activation fragments in the serum, CSF, spinal cord and motor cortex 
of ALS patients. This has also been supported with elevated levels of complement activation 
fragments in various animal models of ALS. Moreover, inhibition of the C5a receptor using 
a specific C5a receptor antagonist ameliorated disease symptoms in a rat model of ALS. 
Collectively, these studies suggest that complement activation may play a crucial role in the 
progression of ALS. Hence reducing complement-induced inflammation using inhibitors to 
target complement factors could be an important therapeutic strategy to treat ALS. 
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